Schneider Downs Wealth Management Advisors LP lifted its position in Eli Lilly and Company (NYSE:LLY) by 47.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,476 shares of the company’s stock after purchasing an additional 472 shares during the period. Schneider Downs Wealth Management Advisors LP’s holdings in Eli Lilly and were worth $341,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in LLY. Atlas Capital Advisors LLC increased its position in shares of Eli Lilly and by 64.6% during the second quarter. Atlas Capital Advisors LLC now owns 107 shares of the company’s stock valued at $25,000 after buying an additional 42 shares during the period. Penserra Capital Management LLC bought a new stake in Eli Lilly and in the second quarter worth $33,000. Financial Insights Inc. bought a new position in Eli Lilly and in the 2nd quarter worth about $36,000. Corsicana & Co. purchased a new stake in shares of Eli Lilly and during the second quarter valued at approximately $46,000. Finally, Sierra Capital LLC bought a new stake in shares of Eli Lilly and in the 1st quarter worth $46,000. Hedge funds and other institutional investors own 81.56% of the company’s stock.
Several equities analysts have recently weighed in on LLY shares. Berenberg Bank upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and increased their price objective for the stock from $240.00 to $270.00 in a research note on Monday, October 11th. Citigroup upgraded Eli Lilly and from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $210.00 to $265.00 in a research report on Wednesday, September 29th. They noted that the move was a valuation call. Morgan Stanley increased their price target on shares of Eli Lilly and from $207.00 to $275.00 and gave the company an “overweight” rating in a report on Wednesday, August 4th. DZ Bank upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $288.00 target price for the company in a report on Thursday, August 5th. Finally, Cowen upped their price objective on Eli Lilly and from $250.00 to $300.00 and gave the company an “outperform” rating in a research report on Monday, August 30th. One analyst has rated the stock with a sell rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Eli Lilly and has an average rating of “Buy” and an average target price of $271.11.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Monday, October 25th. The company reported $1.94 earnings per share for the quarter, missing the consensus estimate of $1.98 by ($0.04). The company had revenue of $6.77 billion for the quarter, compared to analyst estimates of $6.64 billion. Eli Lilly and had a return on equity of 111.51% and a net margin of 21.52%. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.54 earnings per share. Research analysts forecast that Eli Lilly and Company will post 8.01 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 10th. Stockholders of record on Monday, November 15th will be issued a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 1.30%. The ex-dividend date of this dividend is Friday, November 12th. Eli Lilly and’s dividend payout ratio (DPR) is 51.83%.
In other news, major shareholder Lilly Endowment Inc sold 195,000 shares of the business’s stock in a transaction on Thursday, November 4th. The shares were sold at an average price of $268.82, for a total transaction of $52,419,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.13% of the stock is owned by insiders.
About Eli Lilly and
Eli Lilly & Co engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm’s products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.